Cartesian Therapeutics, Inc. · NASDAQ:RNAC
Cartesian Therapeutics — Selecta Biosciences — Stifel 2017 Healthcare Conference
20 slides from Cartesian Therapeutics's conference presentation, Nov 14, 2017
Slide 1: Stifel 2017 Healthcare Conference
Stifel 2017 Healthcare Conference Nasdaq: SELB November 14, 2017
Slide 2: Safe Harbor / Disclaimer
Safe Harbor / Disclaimer 2 Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, the progress of the Phase 1/2 clinical program of SEL-212, the potential of SEL-212 to treat severe gout patie
Slide 3: Corporate Overview
Corporate Overview 3 • Clinical-stage company applying proprietary Synthetic Vaccine Particle (SVP™) platform to avoid unwanted immunogenicity and unlock the full potential of biologic therapies. • Focused on SEL-212 (pegsiticase administered with SVP-Rapamycin); designed to be the first non-immunog
Slide 4: Preventing Unwanted Immunogenicity via Selecta's SVP-Rapamycin Technology Platform
Preventing Unwanted Immunogenicity via Selecta’s SVP-Rapamycin Technology Platform 4 Spleen Preventing ADAs Inducing a tolerogenic response to a biologic drug (antigen) Implementing the message Sending precise instructions Targeting immune cells • By dosing “free biologic” separate from SVP- Rapamyc
Slide 5: SEL-212 for Chronic Severe Gout
SEL-212 for Chronic Severe Gout
Slide 6: SEL-212: Advancing a Potential New Treatment Option for Chronic Severe Gout Patients Toward Phase 3
SEL-212: Advancing a Potential New Treatment Option for Chronic Severe Gout Patients Toward Phase 3 6 Rare and Serious Disease • ~160,000 adults with chronic severe gout treated by U.S. rheumatologists • Debilitating flares and joint-damaging arthritis caused by uric acid deposits; risk of renal and
Slide 7: High Unmet Need in Chronic Severe Gout
High Unmet Need in Chronic Severe Gout • Rapid onset of action - Persistent reduction in SUA - Elimination of tophi • Monthly dosing • Reduced incidence of gout flares • Ability to complete full therapy cycles • Lower incidence of infusion reactions 7 We believe SEL-212 has the potential to address
Slide 8: Phase 1b Single Dose Patient Cohorts
Phase 1b Single Dose Patient Cohorts 8 IMVACS 2016 Presentation. Clinicaltrials.gov NCT02648269 S e ru m U ric A cid ( m g /d L ) 0.03 mg/kg 0.4 mg/kg 0.1 mg/kg 0.4 mg/kg 0.4 mg/kg 0.3 mg/kg 0.4 mg/kg 0.15 mg/kg 0.4 mg/kg 0 2 4 6 8 1 0 0 2 4 6 8 1 0 0 2 4 6 8 1 0 0 2 4 6 8 1 0 0 2 4 6 8 1 0 N = 5 N
Slide 9: Phase 2 Trial Overview
Phase 2 Trial Overview 9 Enrollment Criteria Primary/Secondary Endpoints Design Dosing Stopping Rules As of October 23 • Patients with symptomatic gout and SUA levels >6 mg/dL • Safety, tolerability and pharmacokinetics of multiple doses of SEL-212 and pegsiticase alone • Reduction of SUA levels • R
Slide 10: Clinical Activity in Mid-Dose Cohorts
% of Patients With SUA <6 mg/dL Clinical Activity in Mid-Dose Cohorts 10 Unaudited data reported as of October 23, 2017 | Clinicaltrials.gov NCT02959918 70%* Pegsiticase + SVP-Rapamycin 0.1 mg/kg 0.2 or 0.4 mg/kg Pegsiticase Alone SEL-212 Cohorts 7 & 8** 0 5 0 1 0 0 D a y % P ts S UA <6 mg /dL 0 2 8
Slide 11: Comparison With Control Cohorts Indicates Immune Tolerance
0.2 or 0.4 mg/kg Pegsiticase Alone Pegsiticase alone Cohorts 1 & 2 % of Patients With SUA <6 mg/dL Comparison With Control Cohorts Indicates Immune Tolerance 11 Unaudited data reported as of October 23, 2017 | Clinicaltrials.gov NCT02959918 * Ph1b Day 30 @ 0.1 mg/kg SVP-Rapamycin + 0.4 mg/kg pegsiti
Slide 12: 5 1 1 2 1 1 9 1 2 6 1 3 3 1
0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 6 3 7 0 7 7 8 4 9 1 9 8 1 0 5 1 1 2 1 1 9 1 2 6 1 3 3 1 4 0 0 2 4 6 8 1 0 1 0 2 1 0 3 1 0 4 1 0 5 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 6 3 7 0 7 7 8 4 9 1 9 8 1 0 5 1 1 2 1 1 9 1 2 6 1 3 3 1 4 0 0 2 4 6 8 1 0 1 0 2 1 0 3 1 0 4 1 0 5 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 6 3 7 0
Slide 13: 5 1 1 2 1 1 9 1 2 6 1 3 3 1
0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 6 3 7 0 7 7 8 4 9 1 9 8 1 0 5 1 1 2 1 1 9 1 2 6 1 3 3 1 4 0 0 2 4 6 8 1 0 1 0 2 1 0 3 1 0 4 1 0 5 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 6 3 7 0 7 7 8 4 9 1 9 8 1 0 5 1 1 2 1 1 9 1 2 6 1 3 3 1 4 0 0 2 4 6 8 1 0 1 0 2 1 0 3 1 0 4 1 0 5 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 6 3 7 0
Slide 14: Low Frequency of Gout Flares Observed with SEL-212 Treatment
1 1 2 3 4 5 0 2 0 4 0 6 0 Low Frequency of Gout Flares Observed with SEL-212 Treatment 14 • Data indicate SEL-212 lowers flares initially and over time during treatment • Urate lowering therapies typically increase the incidence of flares at the beginning of therapy Unaudited data as of October 23,
Slide 15: SEL-212 Generally Well Tolerated at Clinically Active Doses
SEL-212 Generally Well Tolerated at Clinically Active Doses 15 • SEL-212 has been generally well tolerated at clinically active doses following >200 administrations • SAEs reported in the Phase 2 trial: - Four were reported not to be or unlikely to be related to study drug: - Seven infusion reaction
Slide 16: SEL-212 Expected to Enter Phase 3 in 2018
SEL-212 Expected to Enter Phase 3 in 2018 16 • Focused on SEL-212 (pegsiticase administered with SVP-Rapamycin); designed to be the first non-immunogenic uricase treatment for chronic severe gout - Phase 2 dose/regimen-finding study: SEL-212 is clinically active and generally well tolerated at 0.08
Slide 17: SEL-212 Program is Informing the Development of Other Product Candidates
SEL-212 Program is Informing the Development of Other Product Candidates 17 Chronic Therapies+ Proprietary program Potential program Single Treatment Chronic Treatment Adult Patients with Chronic Conditions Cancer Patients Pediatric Patients with Life-Threatening Conditions Oncology (SEL-403) Treatm
Slide 18: Spark Therapeutics License Agreement
Spark Therapeutics License Agreement 18 • December 2016 agreement provides Spark Therapeutics with exclusive worldwide rights to Selecta's SVP technology for up to five gene therapy targets • Initial focus on combination of SVP with Spark’s Hemophilia A gene therapy • Among the largest gene therapy
Slide 19: 3Q17 Financial Overview
3Q17 Financial Overview 19 For the Quarter Ended (In thousands, except share and per share data) September 30, 2017 September 30, 2016 Grant & Collaboration Revenue $27 $1,048 Research & Development Expenses 9,504 6,021 General & Administrative Expenses 4,377 2,495 Net Loss Attributable to Common St
Slide 20: Thank You
Se SELECTA Biosciences Thank You
Selecta Biosciences — Stifel 2017 Healthcare Conference on 6ix